Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

NCT02319005 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT02319005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02319005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
March 30, 2017
Enrollment
206 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

amyloid neuropathies, amyloid neuropathies, familial, amyloidosis, hereditary, amyloidosis, hereditary, transthyretin-related, familial transthyretin cardiac amyloidosis, transthyretin (ttr) mediated familial amyloidotic cardiomyopathy (fac)